George, D. J., Clarke, N. W., Santis, M. D., Uemura, H., Fay, A. P., Ürün, Y., Arslan, C., Hong, J. H., Joung, J. Y., Chen, W., Lesage, K., Hoa, N. T. T., Minchev, V., Garbaos, G., Logan, J., Newton, L., Koepp-Norris, J., Khatun, M., Fizazi, K. (2026). Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.14